Optibiotix Health Plc (LON:OPTI) is the topic of conversation with Hybridan researcher and corporate broker Nathan Derren. The company has made great progress since its IPO and Nathan explains what the main drivers will be going forward, why the Human Microbiome is gaining such high attention and how OptiBiotix stacks up in the light of the current regulatory environment.
OptiBiotix Health Plc was formed in March 2012 to develop compounds which modify the human microbiome – the collective genome of the microbes in the body – to prevent and manage human disease. The aim of the company is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. The company has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
